Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reducing Pain and Opioid Use With CBD
NCT05299944Phase 2Completed
- Sponsor
- University of Colorado Denver
- Start
- Mar 2022
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cannabidiol in opioid use disorder (OUD), pain and anxiety disorder (3 arms), sponsored by University of Colorado Denver. Primary endpoints: Reduction in pain medication use at 12 weeks, Reduction in THC use at 12 weeks and 1 more. Started Mar 2022; status: completed.
02
Drugs
cannabidiol
03
Conditions
opioid use disorder (OUD)painanxiety disorder
Beyond the preview
Go deeper on NCT05299944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05299944.